Navigation Links
Common cancer gene sends death order to tiny killer

Scientists at Johns Hopkins have discovered one way the p53 gene does what it's known for—stopping the colon cancer cells. Their report will be published in the June 8 issue of Molecular Cell.

The research team identified a tiny bit of genetic code, a microRNA called miR-34a that participates in p53's uncanny ability to kill cells likely to become malignant because of damaged genes in their nuclei. MicroRNAs are small chains of ribonucleic acid (RNA) made by the same machinery that produces other types of RNA in the cell, such as the messenger RNAs that carry the instructions to make proteins. Once produced, microRNAs stick to messenger RNAs and, like crumpled paper jammed in a copy machine, prevent proteins from being made.

Josh Mendell, M.D., Ph.D., an assistant professor in the McKusick-Nathans Institute of Genetic Medicine, suspected that p53 activates microRNAs like miR-34a because a number of studies have demonstrated that these tiny RNA molecules are frequently abnormal in cancer cells.

"P53 is one of the most commonly mutated genes in human cancers," says Mendell. "And there is now a great deal of evidence that microRNAs themselves can act to either promote cancer or to stop cancer spread."

To test their idea, the team first chemically damaged the DNA of two sets of colon cancer cells, one missing p53 and the other containing healthy p53. They then looked for any of the 500 known human microRNAs that are activated only in cells containing p53.

It turned out that the miR-34a gene is turned on by p53, and in fact, experiments demonstrated that p53 binds directly to the genetic material near miR-34a to promote its activation.

Concluding that p53 controls miR-34a, they next teamed up with Charlie Lowenstein, M.D., and his colleagues in Hopkins's department of medicine to put miR-34a into colon cancer cells. Doing this killed cells that contained p53, but fewer were killed in cells lacking p53, furthe r suggesting that this microRNA gets its kill orders from p53.

When researchers examined pancreatic cancer cells known to contain damaged or missing p53, they found that those cells had limited or zero miR-34a.

"With no p53 gene or miR-34a to stem tumor development, there's no brake in pancreatic cells and uncontrolled growth leads to cancer," says Anirban Maitra, M.B.B.S., associate professor of pathology, oncology and genetic medicine.

Mendell and his team are looking for missing miR-34a in other cancers. If it's a widespread phenomenon, the work could lead to treatments that aim to restore the missing microRNA to cancer cells.


'"/>

Source:Johns Hopkins Medical Institutions


Related biology news :

1. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
2. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
3. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
4. Use of Antibiotics for Acne May Increase Risk of Common Illness
5. Common viruses may cause cancer
6. Common alternative treatment for liver disease is found to be ineffective
7. Common molecular signature identified in solid tumors
8. Common bacteria pirate natural mechanism to get inside cells
9. Commonly used antidepressants may also affect human immune system
10. Common practices at petting zoos put visitors at risk
11. Common enzyme is a key player in DNA repair

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... 2017 The report "Gesture Recognition and Touchless Sensing Market ... - Global Forecast to 2022", published by MarketsandMarkets, the market is expected to ... between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... year,s petition to the White House signed by 120,000 ... generate awareness on the importance of new organic medicines and nutritional ... place. ... this month Health Advance (OTC PINK: HADV ), ... announced its endeavors on this generally recognized as safe ...
(Date:3/29/2017)... ... March 29, 2017 , ... (March 29, 2017) — ... approved as an active member of the Mexican Direct Selling Association A.C. ... consumers in relationship marketing. This professional organization fosters loyal and fair competition among ...
(Date:3/29/2017)... March 29, 2017  Halozyme Therapeutics, Inc. (NASDAQ: ... drug-delivery therapies, today announced that an Oncologic Drug ... Administration voted 11 to 0 that the benefit/risk ... was favorable for patients in the proposed indications ... chronic lymphocytic leukemia. The FDA action date is ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... it is exhibiting in booth 513 at the Association of Community Cancer Centers ... Hotel, March 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations ...
Breaking Biology Technology: